Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma

References

• Dewhirst MW, Thrall DE, MacEwen EG. Spontaneous pet animal cancers In: Teicher BA, editor. Tumor models in cancer research. Totowa, NJ: Humana Press; 2001. pp 565–589.
   Google Scholar
• Hansen K, Khanna C. Spontaneous and genetically engineered animal models: use in preclinical cancer drug development. Eur J Cancer 2004;40:858–880.
   PubMed Web of Science ®Google Scholar
• Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008;8:147–156.
   PubMed Web of Science ®Google Scholar
• Vail DM, Young KM. Canine lymphoma and lymphoid leukemia In: Withrow SJ, Vail DM, editors. Small animal clinical oncology. 4th ed. St. Louis, MO: Saunders; 2007. pp 699–733.
   Google Scholar
• Modiano JF, Breen M, Burnett RC, et al. Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res 2005;65:5654–5661.
   PubMed Web of Science ®Google Scholar
• Breen M, Modiano JF. Evolutionarily conserved cytogenetic changes in hematological malignancies of dogs and humans - man and his best friend share more than companionship. Chromosome Res 2008;16:145–154.
   PubMed Web of Science ®Google Scholar
• Brown KS, Levitt DJ, Shannon M, Link BK. Phase II trial of Remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma. Clin Lymphoma 2001;2:188–190.
   PubMedGoogle Scholar
• DeNardo GL, Tobin E, Chan K, Bradt BM, DeNardo SJ. Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies. Clin Cancer Res 2005;11:7075s–7079s.
   PubMed Web of Science ®Google Scholar
• Stein R, Qu Z, Chen S, Solis D, Hansen HJ, Goldenberg DM. Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab. Blood 2006;108:2736–2744.
   Google Scholar
• Stein R, Gupta P, Cardillo TM, et al. Therapy of B-cell malignancies by anti-HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyper-activation of ERK and JNK MAP kinase signaling pathways. Blood 2010;115:5180–5190.
   PubMed Web of Science ®Google Scholar
• Dechant M, Bruenke J, Valerius T. HLA class II antibodies in the treatment of hematologic malignancies. Semin Oncol 2003;30:465–475.
   PubMed Web of Science ®Google Scholar
• Shi JD, Bullock C, Hall WC, et al. In vivo pharmacodynamic effects of Hu1D10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells. Leuk Lymphoma 2002;43:1303–1312.
   PubMed Web of Science ®Google Scholar
• Rech J, Repp R, Rech D, et al. A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study. Leuk Lymphoma 2006;47:2147–2154.
   PubMed Web of Science ®Google Scholar
• van der Kolk LE, Grillo-Lopez AJ, Baars JW, Hack CE, van Oers MH. Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115:807–811.
   PubMed Web of Science ®Google Scholar
• Stein R, Qu Z, Chen S, et al. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004;10:2868–2878.
   PubMed Web of Science ®Google Scholar
• Veterinary co-operative oncology group – common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:195–213.
   PubMedGoogle Scholar
• Henricsson A, Bergentz SE. Role of platelets and lymphocytes for the hemodynamic effects of rapidly injected antilymphocyte globulin. Eur Surg Res 1978;10:40–49.
   PubMed Web of Science ®Google Scholar
• Mathews KA, Gallivan GJ, Mallard BA. Clinical, biochemical and hematologic evaluation of normal dogs after administration of rabbit anti-dog thymocyte serum. Vet Surg 1993;22:213–220.
   PubMed Web of Science ®Google Scholar
• Nagy ZA, Mooney NA. A novel, alternative pathway of apoptosis triggered through class II major histocompatibility complex molecules. J Mol Med 2003;81:757–765.
   PubMed Web of Science ®Google Scholar
• Mone AP, Huang P, Pelicano H, et al. Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells. Blood 2004;103:1846–1854.
   PubMed Web of Science ®Google Scholar
• Newell MK, VanderWall J, Beard KS, Freed JH. Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes. Proc Natl Acad Sci USA 1993;90:10459–10463.
   PubMed Web of Science ®Google Scholar
• Truman JP, Choqueux C, Tschopp J, et al. HLA class II-mediated death is induced via Fas/Fas ligand interactions in human splenic B lymphocytes. Blood 1997;89:1996–2007.
   PubMed Web of Science ®Google Scholar
• Altomonte M, Visintin A, Tecce R, et al. Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanoma. J Cell Physiol 2004;200:272–276.
   PubMed Web of Science ®Google Scholar
• Aoudjit F, Guo W, Gagnon-Houde JV, et al. HLA-DR signaling inhibits Fas-mediated apoptosis in A375 melanoma cells. Exp Cell Res 2004;299:79–90.
   PubMed Web of Science ®Google Scholar
• Fernández EM, O'Toole PJ, Morrison IE, Cherry RJ, Fernández N. Interaction of HLA-DR with actin microfilaments. Hum Immunol 2003;64:327–337.
   PubMed Web of Science ®Google Scholar
• Guo W, Mourad W, Charron D, Al-Daccak R. Ligation of MHC class II molecules differentially upregulates TNF beta gene expression in B cell lines of different MHC class II haplotypes. Hum Immunol 1999;60:312–322.
   PubMed Web of Science ®Google Scholar
• Coral S, Pucillo C, Leonardi A, Fonsatti E, Altomonte M, Maio M. Triggering of HLA-DR antigens differentially modulates tumor necrosis factor alpha release by B cells at distinct stage of maturation. Cell Growth Differ 1997;8:581–588.
   PubMedGoogle Scholar
• Mourad W, Geha RS, Chatila T. Engagement of major histocompatibility complex class II molecules induces sustained, lymphocyte function-associated molecule 1-dependent cell adhesion. J Exp Med 1990;172:1513–1516.
   PubMed Web of Science ®Google Scholar
• Blancheteau V, Charron D, Mooney N. HLA class II signals sensitize B lymphocytes to apoptosis via Fas/CD95 by increasing FADD recruitment to activated Fas and activation of caspases. Hum Immunol 2002;63:375–383.
   PubMed Web of Science ®Google Scholar
• Elasser D, Valerius T, Repp R, et al. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood 1996;87:3803–3812.
   PubMed Web of Science ®Google Scholar
• Kabelitz D, Janssen O. Growth inhibition of Epstein-Barr virus transformed B cells by anti-HLA-DR antibody L243: possible relationship to L243-induced down regulation of CD23 antigen expression. Cell Immunol 1989;120:21–30.
   PubMed Web of Science ®Google Scholar